Bristol Myers and Microsoft team up for AI lung cancer detection
Bristol Myers Squibb (BMY) has partnered with Microsoft (MSFT) to use AI in the early detection of lung cancer. The collaboration will deploy Microsoft’s AI-enabled radiology platform to help hospitals analyze X-ray and CT scans more efficiently.
The platform uses FDA-cleared AI algorithms through Microsoft’s Precision Imaging Network. It can identify lung disease, including hard-to-detect nodules, and help spot patients at earlier stages of illness.
Expanding access to underserved communities
A key goal of the partnership is to reach medically underserved areas, such as rural hospitals and community clinics across the U.S.
Alexandra Goncalves, Vice President and Head of Digital Health at Bristol Myers Squibb, said: “By combining Microsoft’s scalable radiology solutions with Bristol’s oncology expertise, we’ve created an AI workflow that helps clinicians quickly and accurately identify patients with non-small cell lung cancer and guide them to optimal care and precision therapies.”
AI’s growing role in pharma
Pharmaceutical companies are increasingly using AI to speed up research and development. Automated labs and modeling tools improve efficiency across drug pipelines.
For example, last week AstraZeneca agreed to acquire Modella AI, a Boston-based company, to accelerate oncology drug research.
